Servei de Microbiologia, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau, Sant Quintí 89, 08041 Barcelona, Spain.
Eur J Clin Microbiol Infect Dis. 2013 Feb;32(2):253-9. doi: 10.1007/s10096-012-1737-0. Epub 2012 Sep 7.
The purpose of this investigation was to determine the prevalence of plasmid-mediated AmpC (pAmpC) and carbapenemases in Enterobacteriaceae collected from 35 hospitals in Spain and to establish their epidemiological relationships. We conducted a prospective multi-centre study on pAmpC- or carbapenemase-producing Enterobacteriaceae isolates from clinical samples collected from February to July 2009. The strains suspected to carry pAmpC were resistant or showed intermediate susceptibility to co-amoxiclav and second- or third-generation cephalosporins. Strains suspected to carry a carbapenemase were selected because they showed a minimum inhibitory concentration (MIC) to imipenem >1 mg/L. Polymerase chain reaction (PCR) and a sequencing strategy were used to characterise the enzymes. The clonal relationships between isolates was analysed by pulsed field gel electrophoresis (PFGE). Among 100,132 Enterobacteriaceae isolates collected, 1,654 were compatible with the production of pAmpC or carbapenemases. We found a prevalence of 0.64 % of pAmpC (n = 635) and 0.04 % of carbapenemases (n = 43). The most prevalent pAmpC enzymes were CMY-type (78.3 %), DHA-type (19.5 %), ACC-type (1.6 %) and FOX-type (0.6 %). The CMY-type was the most frequent in Escherichia coli and Proteus mirabilis species, whereas the DHA-type was mainly found in Klebsiella spp. The enzymes involved in carbapenem resistance were VIM-1, IMP-22 and the new IMP-28. Nine new bla genes were described: bla (CMY-54), bla (CMY-55), bla (CMY-56), bla (CMY-57), bla (CMY-96), bla (DHA-6), bla (DHA-7), bla (FOX-8) and bla (IMP-28). The prevalence of pAmpC or carbapenemases found is not negligible. The CMY-types were the predominant pAmpC, whereas the VIM or IMP enzymes were the predominant carbapenemases. Furthermore, we observed a great genetic diversity among pAmpC-producing strains and a close clonal relationship between carbapenemase-producing strains.
本研究旨在确定西班牙 35 家医院收集的肠杆菌科中质粒介导的 AmpC(pAmpC)和碳青霉烯酶的流行率,并确定它们的流行病学关系。我们对 2009 年 2 月至 7 月从临床样本中分离的产 pAmpC 或碳青霉烯酶的肠杆菌科分离株进行了前瞻性多中心研究。疑似携带 pAmpC 的菌株对复方阿莫西林和第二代或第三代头孢菌素表现出耐药或中介敏感性。疑似携带碳青霉烯酶的菌株是因为它们对亚胺培南的最小抑菌浓度(MIC)> 1mg/L。聚合酶链反应(PCR)和测序策略用于鉴定酶。通过脉冲场凝胶电泳(PFGE)分析分离株之间的克隆关系。在收集的 100132 株肠杆菌科分离株中,有 1654 株与 pAmpC 或碳青霉烯酶的产生相符。我们发现 pAmpC 的流行率为 0.64%(n=635),碳青霉烯酶的流行率为 0.04%(n=43)。最常见的 pAmpC 酶为 CMY 型(78.3%)、DHA 型(19.5%)、ACC 型(1.6%)和 FOX 型(0.6%)。CMY 型在大肠埃希菌和奇异变形杆菌中最为常见,而 DHA 型主要在克雷伯菌属中发现。与碳青霉烯类耐药相关的酶为 VIM-1、IMP-22 和新型 IMP-28。描述了 9 个新的 bla 基因:bla(CMY-54)、bla(CMY-55)、bla(CMY-56)、bla(CMY-57)、bla(CMY-96)、bla(DHA-6)、bla(DHA-7)、bla(FOX-8)和 bla(IMP-28)。发现的 pAmpC 或碳青霉烯酶的流行率不容忽视。CMY 型是主要的 pAmpC,而 VIM 或 IMP 酶是主要的碳青霉烯酶。此外,我们观察到产 pAmpC 菌株之间具有很大的遗传多样性,并且产碳青霉烯酶菌株之间存在密切的克隆关系。